Estrogen status is a risk factor for temporomandibular muscle and joint disorders (TMJD) and other craniofacial pain conditions. The basis for estrogen modulation of pain is poorly understood and has often been attributed to long-term genomic effects. However, estrogens also act rapidly through membrane-initiated mechanisms to alter neural activity. To assess if estrogens act rapidly to affect TMJ-responsive neurons, we applied 17β-estradiol (E2) directly at the spinomedullary (Vc/C 1-2 ) region, the initial brainstem site for synaptic integration of TMJ sensory signals, while recording single neuron activity. In ovariectomized female rats, E2 rapidly (within 10 minutes) and reversibly reduced TMJevoked neural activity at the Vc/C 1-2 region. The effect was estrogen receptor (ER) subtype-specific, since ERβ agonists inhibited, while an ERβ agonist enhanced, evoked activity. A membrane-mediated mechanism was indicated, since the membraneimpermeable analogue, E 2 -BSA, mimicked the inhibitory effect of E2 and was prevented by an ER antagonist. This study demonstrated that E2 acted rapidly, through membrane-mediated pathways, and locally at the Vc/C 1-2 region, to modulate sensory signals from the TMJ region. These results were consistent with the hypothesis that estrogens can act rapidly at the level of the trigeminal brainstem complex to influence sensory integration of TMJ-related information.
t emporomandibular muscle and joint disorders (TMJD) represent a family of conditions that present with spontaneous pain of the jaw joint region and are more prevalent in women than men (Maixner, 2009; Bereiter and Okamoto, 2011) . Although estrogen status is a risk factor for TMJD, its relationship with pain expression is poorly understood. Many effects of estrogen in the brain can be attributed to activation of classic estrogen receptor (ER) subtypes, ERα and ERβ, and long-term changes in gene transcription; however, estrogens also act rapidly, by membrane-initiated mechanisms, to alter neuronal excitability and synaptic plasticity (McEwen, 2001; Vasudevan and Pfaff, 2008) . Rapid effects of estrogens on hypothalamic and hippocampal neurons influence reproductive and cognitive functions (Woolley, 2007; Kelly and Ronnekleiv, 2009) . Although in vitro studies have reported that estrogens can act rapidly to modify the activity of peripheral sensory (Chaban et al., 2003; Rowan et al., 2010) and spinal cord neurons (Jiang et al., 2009; Zhong et al., 2010) , it is not known if estrogens can act rapidly to alter the encoding properties of nociceptive trigeminal brainstem neurons with defined receptive field properties recorded in whole animals.
Sensory nerves that supply the TMJ region terminate centrally at the trigeminal subnucleus caudalis/upper cervical cord (Vc/C 1-2 ) junction region (Bereiter and Okamoto, 2011) , a region that shares many features with the spinal dorsal horn, including a high density of ER-positive neurons (Amandusson et al., 1996; Bereiter et al., 2005) . Sensory encoding by TMJresponsive neurons at the Vc/C 1-2 region changes markedly over different stages of the estrous cycle and following 3 days of exogenous E2 treatment, consistent with genomic actions (Okamoto et al., 2003; Tashiro et al., 2007) . However, no study has determined if acute application of E2 at the Vc/C 1-2 region is sufficient to modify the activity of TMJ-responsive neurons.
MEthODs
The animal protocols were approved by the Institutional Animal Care and Use Committee of the University of Minnesota according to the guidelines of the National Institutes of Health (PHS Law 99-158, revised 2002) .
Experimental Preparation
Ovariectomized (OvX) female rats (n = 37, 250-320 g; Sprague-Dawley, Harlan, Indianapolis, IN, USA) were sedated with pentobarbital sodium (60 mg/kg, i.p.), maintained after surgery by infusion of thiopental sodium (20-30 mg/kg/hr), and switched to a mixture of thiopental and gallamine triethiodide (15-20 mg/kg/hr) at the time of recording. Catheters were placed in a femoral artery (blood pressure monitor) and jugular vein (anesthesia), the Vc/C 1-2 rapid Estrogenic Effects on tMJ-responsive brainstem neurons region was exposed for neural recording (see Okamoto et al., 2003; Fig. 1) , and a guide cannula was placed in the TMJ to deliver injections of ATP (1 mM, 20 µL) as described previously (Tashiro et al., 2008) . ATP is a natural constituent of synovial fluid (Ryan et al., 1991) and causes pain after muscle injection in humans (Mork et al., 2003) and nocifensive behavior after TMJ injection in rats (Oliveira et al., 2005) . Adequate depth of anesthesia was confirmed by the absence of cornea and hindlimb withdrawal reflexes prior to gallamine administration, fully constricted pupils, and constant arterial blood pressure and heart rate throughout the experiment. Vaginal smear cytology on the day of the experiment revealed only small leukocytes and confirmed a low estrogen state.
Experimental Design
Neurons were identified by deep probing of the TMJ region and tested by intra-TMJ injections of phosphate-buffered saline (PBS), followed by repeated injections of ATP at 20-minute intervals. All neurons included in this study also received convergent skin input and were classified as nociceptive-specific. Drugs (20 µL) were applied via a micropipette 10 min prior to the ATP stimulus, and, after 10 additional min, the fluid covering the brainstem surface was removed gently by filter paper, and aCSF was applied immediately to prevent drying (Tashiro et al., 2009) . Five treatment groups were assessed: (1) E2 (0.2 and 2 mM, n = 8); (2) ERα-selective agonist, PPT (0.2 and 2 mM, n = 8); (3) ERβ-selective agonist, DPN (0.2 and 2 mM, n = 11; see Harrington et al., 2003) ; (4) membrane-impermeable ER agonist, E 2 -BSA (0.2 and 2 mM, n = 5); and (5) the ER antagonist, ICI182780 (2 mM), followed 10 min later by E 2 -BSA (2 mM, n = 5). For each neuron, ATP-evoked responses were assessed before and after vehicle application to the Vc/C 1-2 surface and then tested after drug application. A single neuron was recorded in each experiment.
Drugs
We used: 17β-estradiol (E2, Sigma, St. Louis, MO, USA); selective ERα agonist, 4,4′,4′′-(4-Propyl-[1H] -pyrazole-1,3,5-triyl) trisphenol (PPT); selective ERβ agonist, 2,3-bis(4-Hydroxyphenyl)-propionitrile (DPN); and non-selective ER antagonist, 7a,17b-[9-[(4,4,5,5,5-Pentafluoropentyl) sulfinyl] nonyl] estra-1,3,5(10) -triene-3,17-diol (ICI 182720) (Tocris, Ellisville, MO, USA); and membrane-impermeable ER agonist, 17β-estradiol-17-hemisuccinate-BSA (E 2 -BSA, Steraloids, Newport, RI, USA). E2, PPT, DPN, and ICI182780 were dissolved initially in 20% DMSO and diluted to a final concentration with artificial CSF (aCSF). E 2 -BSA was dissolved in aCSF, passed through a 3-kDa cut-off filter to remove free estrogens, re-suspended, and used immediately (Chaban et al., 2003) .
Data Analysis
Neural recording data were quantified as a response magnitude (Rmag), equivalent to the "area under the curve", defined as the mean plus 2 times the standard deviation (SD) minus background activity (1 min) subtracted from the total spike count for each 1-second bin. The total Rmag, response duration, and latency were determined as described previously (Okamoto et al., 2003) . Background activity was sampled for 2 min beginning 8 min after vehicle or drug application. The high-threshold convergent cutaneous receptive field (RF) area of each TMJ neuron was mapped with a small forceps (~3 mm 2 ) onto a standardized series of rat face drawings and measured by planimetry with NIH ImageJ software. Data were assessed statistically by analysis of variance (ANOVA) corrected for repeated measures, and individual comparisons were made by the Newman-Keuls test after ANOVA. A p-value of < 0.05 was considered significant.
rEsults Thirty-seven neurons were recorded in superficial laminae at the Vc/C 1-2 region at an average depth of 180 ± 17 µm from the dorsal surface ( Fig. 1A) . All neurons were spontaneously active (2.3 ± 0.5 spikes/sec, n = 37).
Effects of Er Agonists Applied to the Dorsal brainstem surface
The total Rmag evoked by intra-TMJ injections of ATP was not affected by vehicle (~10% DMSO) application (pre-DMSO, 451 ± 46; post-DMSO 474 ± 31 spikes/stimulus, n = 8), whereas a marked dose-related decrease in Rmag was seen after E2 ( Fig.  1B) . Low-(0.2 mM, -45.6 ± 8.7%) and high-dose E2 (2 mM, -63.2 ± 8.4%) significantly reduced (F 3,84 = 12.9, p < 0.001) the ATP-evoked total Rmag (Fig. 1C ). This was a consistent finding, since 4 of 8 units after 0.2 mM E2 and 7 of 8 units after 2 mM E2 were inhibited by > 50% compared with vehicle application. The selective ERα agonist, PPT, produced a similar dose-related reduction in the ATP-evoked response for each of 8 units tested (F 3,84 = 14.4, p < 0.001). By contrast, the selective ERβ agonist, DPN, enhanced ATP-evoked responses (F 3,84 = 6.4, p < 0.001), since 6 of 11 units had an increase of >50% vs. vehicle. Removal of the drug solution followed by topical application of aCSF reversed all drug effects on ATP-evoked responses when tested 10 min later (Fig. 1C ), suggesting a local site of action. Response duration was reduced significantly after high-dose E2 (55 ± 5 sec vs. 29 ± 6 sec, pre-vs. post-drug; F 3,84 = 8.5, p < 0.001) and PPT (59 ± 10 sec vs. 26 ± 7 sec, pre-vs. post-drug; F 3,84 = 9.7, p < 0.001), whereas DPN had no effect (43 ± 3 sec vs. 51 ± 4 sec; F 3,84 = 0.9, p > 0.1). Response latency to intra-TMJ injections of ATP averaged 11.9 ± 2.2 sec (n = 37) and was not affected by any drug treatment (data not shown).
Effects of a Membrane-impermeable Er Agonist
The membrane-impermeable ER agonist, E 2 -BSA, produced a dose-related inhibition of the ATP-evoked response ( Figs. 2A,   2B ; -95 ± 3%; F 3,84 = 12.1, p < 0.001), whereas vehicle (aCSF) applied to the Vc/C 1-2 surface had no effect. E 2 -BSA markedly inhibited the ATP-evoked activity of each unit tested (n = 5, decrease > 80% vs. vehicle). E 2 -BSA also reduced the ATP-evoked response duration (47 ± 7 sec vs. 9 ± 4 sec, pre-vs. post-drug; F 3,84 = 10.4, p < 0.001), whereas response latency was not affected (data not shown). The inhibitory effect of E 2 -BSA was prevented by prior brainstem application of the non-selective ER antagonist, ICI182780 (Figs. 2C, 2D), consistent with the involvement of classic ER subtypes. The spontaneous firing rate of TMJ neurons was also reduced significantly by E 2 -BSA (Fig.  3A) . Both E 2 -BSA (F 1,41 = 10.2, p < 0.005) and PPT (F 1,41 = 4.9, p < 0.05) significantly reduced the background firing of TMJ neurons, while E2 (F 1,41 = 3.1, p < 0.10) and DPN (F 1,41 = 1.4, p > 0.10) had smaller effects (Fig. 3B) . Drugs applied at the Vc/C 1-2 surface had no effect on resting or TMJ-evoked changes in arterial blood pressure (data not shown).
Effects on cutaneous convergent Input to tMJ neurons
To determine if E2 affected the convergent mechanical input to TMJ neurons from skin overlying the TMJ, we mapped the pinch receptive field (RF) area of each neuron with a small forceps before and 10 min after drug application. E2 (2 mM) caused a 12 ± 3.3% decrease in RF area (predrug = 1.4 ± 0.05 vs. post-E2 = 0.90 ± 0.04 cm 2 ; F 1,7 = 11.1, p < 0.025) by 15 min. Similarly, the ERα agonist, PPT (2 mM), caused a 11.2 ± 4.4% decrease in RF area (F 1,6 = 8.0, p < 0.05), whereas the ERβ agonist, DPN (2 mM), had no effect (F 1,7 = 0.14, p > 0.1).
DIscussIOn
This study demonstrated that E2 acted rapidly and locally at the Vc/C 1-2 region to alter the encoding properties of identified TMJ-responsive neurons. The results were consistent with a membrane-initiated mechanism, depended on specific ER subtypes, and suggested a prominent role for E2 on neuronal excitability, since both background activity and stimulus-evoked responses of TMJ neurons were affected significantly.
The basis for estrogen involvement in TMJ nociceptive processing has remained elusive, due partly to the diversity of possible short-and long-term effects and widespread sites for action in the nervous system. Although natural cyclic variations in sex steroids and daily treatments of E2 produced markedly different effects on the activity of TMJ-responsive neurons at the Vc/C 1-2 region (Okamoto et al., 2003; Tashiro et al., 2007) and TMJevoked nocifensive behavior (Clemente et al., 2004) , no previous study had tested if acute local changes in E2 levels were able to alter medullary dorsal horn neural activity. Several lines of evidence presented here supported the hypothesis of a rapid membrane-initiated mechanism. First, the timing of the E2-induced inhibition occurred within 10 min and was reversed rapidly after drug solution removal and a brief washout period. Second, application of E2 and the membrane-impermeable ER agonist, E 2 -BSA, produced similar effects on TMJ-responsive neurons. Previous studies on cultured spinal dorsal root ganglion neurons reported that E2 and E 2 -BSA prevented calcium influx after ATP stimulation by inhibiting voltage-gated calcium channels (Chaban et al., 2003) , a mechanism that could underlie our results. Also, in a spinal cord slice preparation, a selective ERα antagonist rapidly (within 3 min) enhanced the responses of dorsal horn neurons to high-intensity electrical stimulation of sensory nerves (Zhong et al., 2010) , consistent with our finding of inhibition by an ERα agonist. Third, E 2 -BSA-induced inhibition was prevented by an ER antagonist, ICI182780, consistent with actions through classic ER subtypes. A sequential dose regimen was used here, and, although the initial drug dose was removed within 20 min, it cannot be excluded that some effects of the second drug application were due to carryover from the initial drug exposure period. This seemed unlikely, since even low-dose E2 inhibited (> 50% decrease) the ATP-evoked response in 4 of 8 TMJ neurons. A concern regarding E2 activation via membraneinitiated pathways is that the doses required are often higher than those needed to activate nuclear-initiated pathways (Micevych and Mermelstein, 2008) . The E2 dose range used here (0.78 -7.8 µg in 20 µL) was similar to that shown to affect foot withdrawal latencies to noxious heat after spinal administration in the quail (Evrard and Balthazart, 2004) . Although lower doses of E2 have been reported to reduce muscle-evoked cardiovascular reflexes after topical spinal cord application, the E2 exposure period was 2 hrs (Schmitt et al., 2006) , whereas drugs were applied for less than 20 min in the present study.
A major finding was that selective activation of ERα and ERβ differentially affected the response properties of TMJ neurons. The ERα agonist, PPT, inhibited ATP-evoked responses and background activity, whereas the selective ERβ agonist, DPN, enhanced ATP-evoked responses with no effect on background activity. PPT also reduced the size of the convergent cutaneous RF area of TMJ neurons, whereas DPN had no effect. This suggested that ER-dependent mechanisms regulate inputs from cutaneous as well as deep craniofacial tissues onto second-order TMJ neurons. The basis for the differential effects of ERα vs. ERβ on the encoding properties of TMJ neurons is not certain and may involve structural as well as physiological mechanisms. In the mouse spinal dorsal horn, nearly all interneurons in lamina II that expressed ERβ also contained ERα (Fan et al., 2007) . In the hypothalamus, ERα and ERβ were often co-localized in singlegonadotrophin-releasing hormone (GnRH) neurons; however, the extent of co-localization varied over different stages of the estrous cycle (Hu et al., 2008) . Interestingly, in that study, although ERα and ERβ agonists had opposite effects on neuronal firing rates and cAMP production, individual GnRH cells were either inhibited or facilitated by E2. By contrast, E2, E 2 -BSA, and PPT produced only inhibition in our study. One explanation for this finding was that membrane-bound ERs were mainly of the ERα subtype. The site of E2 action relative to the recorded TMJ neural activity could have been post-synaptic on central neurons or pre-synaptic on central terminals of primary afferent fibers. Trigeminal ganglion (Bereiter et al., 2005) and spinal dorsal root ganglion neurons express ERα and ERβ subtypes (Bennett et al., 2003) , though few neurons express both ER subtypes (Papka and Storey-Workley, 2002) . Intra-TMJ co-injection of E2 with formalin reduced aversive behaviors, suggesting a peripheral site of action (Favaro-Moreira et al., 2009) . Alternatively, topical E2 may have acted centrally on TMJ neurons or local interneurons that, in turn, projected to the recorded TMJ neuron. A central site of action for E2 was supported by the rapid and ER subtype-selective change in the convergent cutaneous RF area of TMJ neurons. Rapid changes in the cutaneous RF area of dorsal horn neurons are generally accepted as evidence of a central neural mechanism of action (Laird and Cervero, 1989) .
The secretory pattern of E2 is characterized by rapid pulses of several minutes' duration, riding on longer term changes in plasma concentration over different stages of the reproductive cycle (Licinio et al., 1998) . Although most studies concerned with sex hormones and sensory function have focused on effects due to long-term exposure, rapid changes in estrogen levels may also play a role. For example, structural changes in dendritic spines of central neurons occur as early as 30 min after elevation in E2 (Srivastava et al., 2008; Phan et al., 2011) . The exact relationship between the rapid effects of E2 on TMJ-responsive Vc/C 1-2 neurons and TMJ nociceptive processing is not known; however, one possibility is that rapid effects trigger downstream signaling cascades that, if sustained, as would be expected in normally cycling females, may lead to long-term changes in central neural circuits through genomic mechanisms.
